In line with those studies, we showed that single as well as multiple low-dose infusion of HUCBC significantly reduced amyloidogenic APP processing, Aβ and β-amyloid plaque accumulation, glial neuroinflammation, and cognitive impairments in preclinical AD mouse models11,12. Here, APP is linked to Alzheimer disease.